And Then There Was One: NewLink Genetics Refocuses Efforts On Indoximod, Its Remaining, Undervalued

Company: NewLink Genetics Corp; NASDAQ: NLNK


Market Cap: ~$235 M

Cash: ~$108M (as of 2Q17)

Burn: ~$27M/Q (as of 2Q17)

Near-term Binary Events:

  • Presentation of updated data from Phase 2 study of indoximod plus gemcitabine/nab-paclitaxel in metastatic pancreatic cancer in Q4 2017 or Q1 2018

Investment Thesis:

NewLink Genetics has faced many setbacks, including most recently disappointing data in its Phase 2 metastatic breast cancer trial with its indirect IDO inhibitor indoximod and Genentech pulling out of the co-development of the direct IDO inhibitor GDC-0919. However, the company has recently refocused its pipeline around indoximod, which has shown good results at least in melanoma, and with a valuation near its all-time low, AMP Biotech Research is cautiously optimistic about the current investment opportunity in NewLink...

Read the rest of our report here

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon